These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26997933)

  • 1. Hypersensitivity Reaction to Insulin Glargine and Insulin Detemir in a Pediatric Patient: A Case Report.
    Badik J; Chen J; Letvak K; So TY
    J Pediatr Pharmacol Ther; 2016; 21(1):85-91. PubMed ID: 26997933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting insulin allergy in a diabetic child.
    Mastrorilli C; Rizzuti L; Cangelosi AM; Iovane B; Chiari G; Caffarelli C
    Int J Immunopathol Pharmacol; 2017 Jun; 30(2):174-177. PubMed ID: 28368217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful management of type IV hypersensitivity reactions to human insulin analogue with injecting mixtures of biphasic insulin aspart and dexamethasone.
    Wen WL; Tsai KB; Lin YH; Hwang SJ; Hsiao PJ; Shin SJ; Hung WW
    J Formos Med Assoc; 2019 Apr; 118(4):843-848. PubMed ID: 30704815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature.
    Mishra S; Connors L; Tugwell B
    Diabet Med; 2018 May; 35(5):663-666. PubMed ID: 29381818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful management of severe diabetic ketoacidosis in a patient with type 2 diabetes with insulin allergy: a case report.
    Nguyen AD; Luong CQ; Chu HC; Nguyen VKD; Nguyen CV; Nguyen TA; Nguyen QH; Mai TD; Nguyen DV; Nguyen BQ; Tran TH; Dao PV; Nguyen DT; Nguyen NN; Do SN
    BMC Endocr Disord; 2019 Nov; 19(1):121. PubMed ID: 31711488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
    Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes.
    Asias BD; Stock EM; Small NL; Getchell KE; Patel JR; Krause JD; Cavness S; Dzenowski CL; Ta M
    J Diabetes Metab Disord; 2015; 14():53. PubMed ID: 26120575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
    Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.
    Fink H; Herbert C; Gilor C
    Domest Anim Endocrinol; 2018 Jul; 64():17-30. PubMed ID: 29709796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
    Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
    Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glargine.
    Wu P; Ji C; Wang M; Zou S; Ge W
    Ann Endocrinol (Paris); 2013 Feb; 74(1):56-8. PubMed ID: 23351561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir.
    O'goshi K; Serup J; Blaaholm B; Thomsen HK; Rossing P; Tarnow L
    Skin Res Technol; 2011 Nov; 17(4):411-9. PubMed ID: 21729174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.
    Bilz S; Flückiger M; Meienberg F; Falconnier C; Keller U; Puder JJ
    PLoS One; 2018; 13(8):e0202007. PubMed ID: 30114246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial.
    Cherubini V; Pintaudi B; Iannilli A; Pambianchi M; Ferrito L; Nicolucci A
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):276-82. PubMed ID: 27023008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
    Owens DR; Bolli GB
    Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.